Skip to main content
Top
Published in: Arthritis Research & Therapy 3/2013

01-06-2013 | Review

Scleroderma pathogenesis: a pivotal role for fibroblasts as effector cells

Authors: Adrian J Gilbane, Christopher P Denton, Alan M Holmes

Published in: Arthritis Research & Therapy | Issue 3/2013

Login to get access

Abstract

Scleroderma (systemic sclerosis; SSc) is characterised by fibrosis of the skin and internal organs in the context of autoimmunity and vascular perturbation. Overproduction of extracellular matrix components and loss of specialised epithelial structures are analogous to the process of scar formation after tissue injury. Fibroblasts are the resident cells of connective tissue that become activated at sites of damage and are likely to be important effector cells in SSc. Differentiation into myofibroblasts is a hallmark process, although the mechanisms and cellular origins of this important fibroblastic cell are still unclear. This article reviews fibroblast biology in the context of SSc and highlights the potentially important place of fibroblast effector cells in fibrosis. Moreover, the heterogeneity of fibroblast properties, multiplicity of regulatory pathways and diversity of origin for myofibroblasts may underpin clinical diversity in SSc, and provide novel avenues for targeted therapy.
Appendix
Available only for authorised users
Literature
1.
go back to reference Gabrielli A, Svegliati S, Moroncini G, Amico D: New insights into the role of oxidative stress in scleroderma fibrosis. Open Rheumatol J. 2012, 6: 87-95. 10.2174/1874312901206010087.PubMedCentralCrossRefPubMed Gabrielli A, Svegliati S, Moroncini G, Amico D: New insights into the role of oxidative stress in scleroderma fibrosis. Open Rheumatol J. 2012, 6: 87-95. 10.2174/1874312901206010087.PubMedCentralCrossRefPubMed
2.
go back to reference Gabrielli A, Avvedimento EV, Krieg T: Scleroderma. N Engl J Med. 2009, 360: 1989-2003. 10.1056/NEJMra0806188.CrossRefPubMed Gabrielli A, Avvedimento EV, Krieg T: Scleroderma. N Engl J Med. 2009, 360: 1989-2003. 10.1056/NEJMra0806188.CrossRefPubMed
3.
go back to reference Riemekasten G, Philippe A, Näther M, Slowinski T, Müller DN, Heidecke H, Matucci-Cerinic M, Czirják L, Lukitsch I, Becker M, Kill A, van Laar JM, Catar R, Luft FC, Burmester GR, Hegner B, Dragun D: Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis. 2011, 70: 530-536. 10.1136/ard.2010.135772.CrossRefPubMed Riemekasten G, Philippe A, Näther M, Slowinski T, Müller DN, Heidecke H, Matucci-Cerinic M, Czirják L, Lukitsch I, Becker M, Kill A, van Laar JM, Catar R, Luft FC, Burmester GR, Hegner B, Dragun D: Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis. 2011, 70: 530-536. 10.1136/ard.2010.135772.CrossRefPubMed
4.
go back to reference Cepeda EJ, Reveille JD: Autoantibodies in systemic sclerosis and fibrosing syndromes: clinical indications and relevance. Curr Opin Rheumatol. 2004, 16: 723-732. 10.1097/01.bor.0000144760.37777.fa.CrossRefPubMed Cepeda EJ, Reveille JD: Autoantibodies in systemic sclerosis and fibrosing syndromes: clinical indications and relevance. Curr Opin Rheumatol. 2004, 16: 723-732. 10.1097/01.bor.0000144760.37777.fa.CrossRefPubMed
5.
go back to reference Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G: The myofibroblast: one function, multiple origins. Am J Pathol. 2007, 170: 1807-1816. 10.2353/ajpath.2007.070112.PubMedCentralCrossRefPubMed Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G: The myofibroblast: one function, multiple origins. Am J Pathol. 2007, 170: 1807-1816. 10.2353/ajpath.2007.070112.PubMedCentralCrossRefPubMed
6.
go back to reference McAnulty RJ, Campa JS, Cambrey AD, Laurent GJ: The effect of transforming growth factor beta on rates of procollagen synthesis and degradation in vitro. Biochim Biophys Acta. 1991, 1091: 231-235. 10.1016/0167-4889(91)90066-7.CrossRefPubMed McAnulty RJ, Campa JS, Cambrey AD, Laurent GJ: The effect of transforming growth factor beta on rates of procollagen synthesis and degradation in vitro. Biochim Biophys Acta. 1991, 1091: 231-235. 10.1016/0167-4889(91)90066-7.CrossRefPubMed
7.
go back to reference Denton CP, Black CM, Abraham DJ: Mechanisms and consequences of fibrosis in systemic sclerosis. Nat Clin Practice Rheumatol. 2006, 2: 134-144.CrossRef Denton CP, Black CM, Abraham DJ: Mechanisms and consequences of fibrosis in systemic sclerosis. Nat Clin Practice Rheumatol. 2006, 2: 134-144.CrossRef
8.
go back to reference Leask A, Abraham DJ: TGFβ signaling and the fibrotic response. FASEB J. 2004, 18: 816-827. 10.1096/fj.03-1273rev.CrossRefPubMed Leask A, Abraham DJ: TGFβ signaling and the fibrotic response. FASEB J. 2004, 18: 816-827. 10.1096/fj.03-1273rev.CrossRefPubMed
9.
go back to reference Young-Min SA, Beeton C, Laughton R, Plumpton T, Bartram S, Murphy G, Black C, Cawston TE: Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls. Ann Rheum Dis. 2001, 60: 846-851.PubMedCentralCrossRefPubMed Young-Min SA, Beeton C, Laughton R, Plumpton T, Bartram S, Murphy G, Black C, Cawston TE: Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls. Ann Rheum Dis. 2001, 60: 846-851.PubMedCentralCrossRefPubMed
10.
go back to reference Leask A: Getting out of a sticky situation: targeting the myofibroblast in scleroderma. Open Rheumatol J. 2012, 6: 163-169. 10.2174/1874312901206010163.PubMedCentralCrossRefPubMed Leask A: Getting out of a sticky situation: targeting the myofibroblast in scleroderma. Open Rheumatol J. 2012, 6: 163-169. 10.2174/1874312901206010163.PubMedCentralCrossRefPubMed
11.
go back to reference Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA: Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol. 2002, 3: 349-363. 10.1038/nrm809.CrossRefPubMed Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA: Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol. 2002, 3: 349-363. 10.1038/nrm809.CrossRefPubMed
12.
go back to reference Shi-Wen X, Thompson K, Khan K, Liu S, Murphy-Marshman H, Baron M, Denton CP, Leask A, Abraham DJ: Focal adhesion kinase and reactive oxygen species contribute to the persistent fibrotic phenotype of lesional scleroderma fibroblasts. Rheumatology. 2012, 51: 2146-2154. 10.1093/rheumatology/kes234.CrossRefPubMed Shi-Wen X, Thompson K, Khan K, Liu S, Murphy-Marshman H, Baron M, Denton CP, Leask A, Abraham DJ: Focal adhesion kinase and reactive oxygen species contribute to the persistent fibrotic phenotype of lesional scleroderma fibroblasts. Rheumatology. 2012, 51: 2146-2154. 10.1093/rheumatology/kes234.CrossRefPubMed
13.
go back to reference Chen Y, Shi-Wen X, van Beek J, Kennedy L, McLeod M, Renzoni EA, Bou-Gharios G, Wilcox-Adelman S, Goetinck PF, Eastwood M, Black CM, Abraham DJ, Leask A: Matrix contraction by dermal fibroblasts requires transforming growth factor-beta/activin-linked kinase 5, heparan sulfate-containing proteoglycans, and MEK/ERK: insights into pathological scarring in chronic fibrotic disease. Am J Pathol. 2005, 167: 1699-1711. 10.1016/S0002-9440(10)61252-7.PubMedCentralCrossRefPubMed Chen Y, Shi-Wen X, van Beek J, Kennedy L, McLeod M, Renzoni EA, Bou-Gharios G, Wilcox-Adelman S, Goetinck PF, Eastwood M, Black CM, Abraham DJ, Leask A: Matrix contraction by dermal fibroblasts requires transforming growth factor-beta/activin-linked kinase 5, heparan sulfate-containing proteoglycans, and MEK/ERK: insights into pathological scarring in chronic fibrotic disease. Am J Pathol. 2005, 167: 1699-1711. 10.1016/S0002-9440(10)61252-7.PubMedCentralCrossRefPubMed
14.
go back to reference Whitfield ML, Finlay DR, Murray JI, Troyanskaya OG, Chi JT, Pergamenschikov A, McCalmont TH, Brown PO, Botstein D, Connolly MK: Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci USA. 2003, 100: 12319-12324. 10.1073/pnas.1635114100.PubMedCentralCrossRefPubMed Whitfield ML, Finlay DR, Murray JI, Troyanskaya OG, Chi JT, Pergamenschikov A, McCalmont TH, Brown PO, Botstein D, Connolly MK: Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci USA. 2003, 100: 12319-12324. 10.1073/pnas.1635114100.PubMedCentralCrossRefPubMed
15.
go back to reference Sargent JL, Milano A, Bhattacharyya S, Varga J, Connolly MK, Chang HY, Whitfield ML: A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity. J Invest Dermatol. 2010, 130: 694-705. 10.1038/jid.2009.318.CrossRefPubMed Sargent JL, Milano A, Bhattacharyya S, Varga J, Connolly MK, Chang HY, Whitfield ML: A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity. J Invest Dermatol. 2010, 130: 694-705. 10.1038/jid.2009.318.CrossRefPubMed
16.
go back to reference Greenblatt MB, Sargent JL, Farina G, Tsang K, Lafyatis R, Glimcher LH, Whitfield ML, Aliprantis AO: Interspecies comparison of human and murine scleroderma reveals IL-13 and CCL2 as disease subset-specific targets. Am J Pathol. 2012, 180: 1080-1094. 10.1016/j.ajpath.2011.11.024.PubMedCentralCrossRefPubMed Greenblatt MB, Sargent JL, Farina G, Tsang K, Lafyatis R, Glimcher LH, Whitfield ML, Aliprantis AO: Interspecies comparison of human and murine scleroderma reveals IL-13 and CCL2 as disease subset-specific targets. Am J Pathol. 2012, 180: 1080-1094. 10.1016/j.ajpath.2011.11.024.PubMedCentralCrossRefPubMed
17.
go back to reference Parsonage G, Filer AD, Haworth O, Nash GB, Rainger GE, Salmon M, Buckley CD: A stromal address code defined by fibroblasts. Trends Immunol. 2005, 26: 150-156. 10.1016/j.it.2004.11.014.PubMedCentralCrossRefPubMed Parsonage G, Filer AD, Haworth O, Nash GB, Rainger GE, Salmon M, Buckley CD: A stromal address code defined by fibroblasts. Trends Immunol. 2005, 26: 150-156. 10.1016/j.it.2004.11.014.PubMedCentralCrossRefPubMed
18.
go back to reference Chang HY, Chi JT, Dudoit S, Bondre C, van de Rijn M, Botstein D, Brown PO: Diversity, topographic differentiation, and positional memory in human fibroblasts. Proc Natl Acad Sci USA. 2002, 99: 12877-12882. 10.1073/pnas.162488599.PubMedCentralCrossRefPubMed Chang HY, Chi JT, Dudoit S, Bondre C, van de Rijn M, Botstein D, Brown PO: Diversity, topographic differentiation, and positional memory in human fibroblasts. Proc Natl Acad Sci USA. 2002, 99: 12877-12882. 10.1073/pnas.162488599.PubMedCentralCrossRefPubMed
19.
go back to reference Hashimoto N, Phan SH, Imaizumi K, Matsuo M, Nakashima H, Kawabe T, Shimokata K, Hasegawa Y: Endothelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 2010, 43: 161-172. 10.1165/rcmb.2009-0031OC.PubMedCentralCrossRefPubMed Hashimoto N, Phan SH, Imaizumi K, Matsuo M, Nakashima H, Kawabe T, Shimokata K, Hasegawa Y: Endothelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 2010, 43: 161-172. 10.1165/rcmb.2009-0031OC.PubMedCentralCrossRefPubMed
20.
go back to reference Arciniegas E, Neves CY, Carrillo LM, Zambrano EA, Ramirez R: Endothelial-mesenchymal transition occurs during embryonic pulmonary artery development. Endothelium. 2005, 12: 193-200. 10.1080/10623320500227283.CrossRefPubMed Arciniegas E, Neves CY, Carrillo LM, Zambrano EA, Ramirez R: Endothelial-mesenchymal transition occurs during embryonic pulmonary artery development. Endothelium. 2005, 12: 193-200. 10.1080/10623320500227283.CrossRefPubMed
21.
go back to reference Willis BC, Borok Z: TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease. Am J Physiol Lung Cell Mol Physiol. 2007, 293: L525-534. 10.1152/ajplung.00163.2007.CrossRefPubMed Willis BC, Borok Z: TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease. Am J Physiol Lung Cell Mol Physiol. 2007, 293: L525-534. 10.1152/ajplung.00163.2007.CrossRefPubMed
22.
go back to reference Frid MG, Kale VA, Stenmark KR: Mature vascular endothelium can give rise to smooth muscle cells via endothelial-mesenchymal transdifferentiation: in vitro analysis. Circ Res. 2002, 90: 1189-1196. 10.1161/01.RES.0000021432.70309.28.CrossRefPubMed Frid MG, Kale VA, Stenmark KR: Mature vascular endothelium can give rise to smooth muscle cells via endothelial-mesenchymal transdifferentiation: in vitro analysis. Circ Res. 2002, 90: 1189-1196. 10.1161/01.RES.0000021432.70309.28.CrossRefPubMed
24.
go back to reference Phillips RJ, Burdick MD, Hong K, Lutz MA, Murray LA, Xue YY, Belperio JA, Keane MP, Strieter RM: Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest. 2004, 114: 438-446.PubMedCentralCrossRefPubMed Phillips RJ, Burdick MD, Hong K, Lutz MA, Murray LA, Xue YY, Belperio JA, Keane MP, Strieter RM: Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest. 2004, 114: 438-446.PubMedCentralCrossRefPubMed
25.
go back to reference Hoyles RK, Derrett-Smith EC, Khan K, Shiwen X, Howat SL, Wells AU, Abraham DJ, Denton CP: An essential role for resident fibroblasts in experimental lung fibrosis is defined by lineage-specific deletion of high-affinity type II transforming growth factor beta receptor. Am J Respir Crit Care Med. 2011, 183: 249-261. 10.1164/rccm.201002-0279OC.CrossRefPubMed Hoyles RK, Derrett-Smith EC, Khan K, Shiwen X, Howat SL, Wells AU, Abraham DJ, Denton CP: An essential role for resident fibroblasts in experimental lung fibrosis is defined by lineage-specific deletion of high-affinity type II transforming growth factor beta receptor. Am J Respir Crit Care Med. 2011, 183: 249-261. 10.1164/rccm.201002-0279OC.CrossRefPubMed
26.
go back to reference Budd DC, Holmes AM: Targeting TGFbeta superfamily ligand accessory proteins as novel therapeutics for chronic lung disorders. Pharmacol Ther. 2012, 135: 279-291. 10.1016/j.pharmthera.2012.06.001.CrossRefPubMed Budd DC, Holmes AM: Targeting TGFbeta superfamily ligand accessory proteins as novel therapeutics for chronic lung disorders. Pharmacol Ther. 2012, 135: 279-291. 10.1016/j.pharmthera.2012.06.001.CrossRefPubMed
27.
go back to reference Rajkumar VS, Howell K, Csiszar K, Denton CP, Black CM, Abraham DJ: Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis. Arthritis Res Ther. 2005, 7: R1113-1123. 10.1186/ar1790.PubMedCentralCrossRefPubMed Rajkumar VS, Howell K, Csiszar K, Denton CP, Black CM, Abraham DJ: Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis. Arthritis Res Ther. 2005, 7: R1113-1123. 10.1186/ar1790.PubMedCentralCrossRefPubMed
28.
go back to reference Dulauroy S, Di Carlo SE, Langa F, Eberl G, Peduto L: Lineage tracing and genetic ablation of ADAM12(+) perivascular cells identify a major source of profibrotic cells during acute tissue injury. Nat Med. 2012, Dulauroy S, Di Carlo SE, Langa F, Eberl G, Peduto L: Lineage tracing and genetic ablation of ADAM12(+) perivascular cells identify a major source of profibrotic cells during acute tissue injury. Nat Med. 2012,
29.
go back to reference Shi-Wen X, Renzoni EA, Kennedy L, Howat S, Chen Y, Pearson JD, Bou-Gharios G, Dashwood MR, du Bois RM, Black CM, Denton CP, Abraham DJ, Leask A: Endogenous endothelin-1 signaling contributes to type I collagen and CCN2 overexpression in fibrotic fibroblasts. Matrix Biol. 2007, 26: 625-632. 10.1016/j.matbio.2007.06.003.CrossRefPubMed Shi-Wen X, Renzoni EA, Kennedy L, Howat S, Chen Y, Pearson JD, Bou-Gharios G, Dashwood MR, du Bois RM, Black CM, Denton CP, Abraham DJ, Leask A: Endogenous endothelin-1 signaling contributes to type I collagen and CCN2 overexpression in fibrotic fibroblasts. Matrix Biol. 2007, 26: 625-632. 10.1016/j.matbio.2007.06.003.CrossRefPubMed
30.
go back to reference Chesney J, Bucala R: Peripheral blood fibrocytes: novel fibroblast-like cells that present antigen and mediate tissue repair. Biochem Soc Trans. 1997, 25: 520-524.CrossRefPubMed Chesney J, Bucala R: Peripheral blood fibrocytes: novel fibroblast-like cells that present antigen and mediate tissue repair. Biochem Soc Trans. 1997, 25: 520-524.CrossRefPubMed
31.
go back to reference Yeager ME, Nguyen CM, Belchenko DD, Colvin KL, Takatsuki S, Ivy DD, Stenmark KR: Circulating fibrocytes are increased in children and young adults with pulmonary hypertension. Eur Respir J. 2012, 39: 104-111. 10.1183/09031936.00072311.PubMedCentralCrossRefPubMed Yeager ME, Nguyen CM, Belchenko DD, Colvin KL, Takatsuki S, Ivy DD, Stenmark KR: Circulating fibrocytes are increased in children and young adults with pulmonary hypertension. Eur Respir J. 2012, 39: 104-111. 10.1183/09031936.00072311.PubMedCentralCrossRefPubMed
32.
go back to reference Katebi M, Fernandez P, Chan ES, Cronstein BN: Adenosine A2A receptor blockade or deletion diminishes fibrocyte accumulation in the skin in a murine model of scleroderma, bleomycin-induced fibrosis. Inflammation. 2008, 31: 299-303. 10.1007/s10753-008-9078-y.PubMedCentralCrossRefPubMed Katebi M, Fernandez P, Chan ES, Cronstein BN: Adenosine A2A receptor blockade or deletion diminishes fibrocyte accumulation in the skin in a murine model of scleroderma, bleomycin-induced fibrosis. Inflammation. 2008, 31: 299-303. 10.1007/s10753-008-9078-y.PubMedCentralCrossRefPubMed
33.
go back to reference Field JJ, Burdick MD, DeBaun MR, Strieter BA, Liu L, Mehrad B, Rose CE, Linden J, Strieter RM: The role of fibrocytes in sickle cell lung disease. PloS One. 2012, 7: e33702-10.1371/journal.pone.0033702.PubMedCentralCrossRefPubMed Field JJ, Burdick MD, DeBaun MR, Strieter BA, Liu L, Mehrad B, Rose CE, Linden J, Strieter RM: The role of fibrocytes in sickle cell lung disease. PloS One. 2012, 7: e33702-10.1371/journal.pone.0033702.PubMedCentralCrossRefPubMed
34.
go back to reference Tourkina E, Bonner M, Oates J, Hofbauer A, Richard M, Znoyko S, Visconti RP, Zhang J, Hatfield CM, Silver RM, Hoffman S: Altered monocyte and fibrocyte phenotype and function in scleroderma interstitial lung disease: reversal by caveolin-1 scaffolding domain peptide. Fibrogenesis Tissue Repair. 2011, 4: 15-10.1186/1755-1536-4-15.PubMedCentralCrossRefPubMed Tourkina E, Bonner M, Oates J, Hofbauer A, Richard M, Znoyko S, Visconti RP, Zhang J, Hatfield CM, Silver RM, Hoffman S: Altered monocyte and fibrocyte phenotype and function in scleroderma interstitial lung disease: reversal by caveolin-1 scaffolding domain peptide. Fibrogenesis Tissue Repair. 2011, 4: 15-10.1186/1755-1536-4-15.PubMedCentralCrossRefPubMed
35.
go back to reference Lee CG, Homer RJ, Cohn L, Link H, Jung S, Craft JE, Graham BS, Johnson TR, Elias JA: Transgenic overexpression of interleukin (IL)-10 in the lung causes mucus metaplasia, tissue inflammation, and airway remodeling via IL-13-dependent and -independent pathways. J Biol Chem. 2002, 277: 35466-35474. 10.1074/jbc.M206395200.CrossRefPubMed Lee CG, Homer RJ, Cohn L, Link H, Jung S, Craft JE, Graham BS, Johnson TR, Elias JA: Transgenic overexpression of interleukin (IL)-10 in the lung causes mucus metaplasia, tissue inflammation, and airway remodeling via IL-13-dependent and -independent pathways. J Biol Chem. 2002, 277: 35466-35474. 10.1074/jbc.M206395200.CrossRefPubMed
36.
go back to reference Andersson-Sjoland A, de Alba CG, Nihlberg K, Becerril C, Ramirez R, Pardo A, Westergren-Thorsson G, Selman M: Fibrocytes are a potential source of lung fibroblasts in idiopathic pulmonary fibrosis. Int J Biochem Cell Biol. 2008, 40: 2129-2140. 10.1016/j.biocel.2008.02.012.CrossRefPubMed Andersson-Sjoland A, de Alba CG, Nihlberg K, Becerril C, Ramirez R, Pardo A, Westergren-Thorsson G, Selman M: Fibrocytes are a potential source of lung fibroblasts in idiopathic pulmonary fibrosis. Int J Biochem Cell Biol. 2008, 40: 2129-2140. 10.1016/j.biocel.2008.02.012.CrossRefPubMed
37.
go back to reference Bucala R, Spiegel LA, Chesney J, Hogan M, Cerami A: Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med. 1994, 1: 71-81.PubMedCentralPubMed Bucala R, Spiegel LA, Chesney J, Hogan M, Cerami A: Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med. 1994, 1: 71-81.PubMedCentralPubMed
38.
go back to reference Chan ES, Fernandez P, Merchant AA, Montesinos MC, Trzaska S, Desai A, Tung CF, Khoa DN, Pillinger MH, Reiss AB, Tomic-Canic M, Chen JF, Schwarzschild MA, Cronstein BN: Adenosine A2A receptors in diffuse dermal fibrosis: pathogenic role in human dermal fibroblasts and in a murine model of scleroderma. Arthritis Rheum. 2006, 54: 2632-2642. 10.1002/art.21974.CrossRefPubMed Chan ES, Fernandez P, Merchant AA, Montesinos MC, Trzaska S, Desai A, Tung CF, Khoa DN, Pillinger MH, Reiss AB, Tomic-Canic M, Chen JF, Schwarzschild MA, Cronstein BN: Adenosine A2A receptors in diffuse dermal fibrosis: pathogenic role in human dermal fibroblasts and in a murine model of scleroderma. Arthritis Rheum. 2006, 54: 2632-2642. 10.1002/art.21974.CrossRefPubMed
39.
go back to reference Sonnylal S, Denton CP, Zheng B, Keene DR, He R, Adams HP, Vanpelt CS, Geng YJ, Deng JM, Behringer RR, de Crombrugghe B: Postnatal induction of transforming growth factor beta signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma. Arthritis Rheum. 2007, 56: 334-344. 10.1002/art.22328.CrossRefPubMed Sonnylal S, Denton CP, Zheng B, Keene DR, He R, Adams HP, Vanpelt CS, Geng YJ, Deng JM, Behringer RR, de Crombrugghe B: Postnatal induction of transforming growth factor beta signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma. Arthritis Rheum. 2007, 56: 334-344. 10.1002/art.22328.CrossRefPubMed
40.
go back to reference Loeys BL, Chen J, Neptune ER, Judge DP, Podowski M, Holm T, Meyers J, Leitch CC, Katsanis N, Sharifi N, Xu FL, Myers LA, Spevak PJ, Cameron DE, De Backer J, Hellemans J, Chen Y, Davis EC, Webb CL, Kress W, Coucke P, Rifkin DB, De Paepe AM, Dietz HC: A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet. 2005, 37: 275-281. 10.1038/ng1511.CrossRefPubMed Loeys BL, Chen J, Neptune ER, Judge DP, Podowski M, Holm T, Meyers J, Leitch CC, Katsanis N, Sharifi N, Xu FL, Myers LA, Spevak PJ, Cameron DE, De Backer J, Hellemans J, Chen Y, Davis EC, Webb CL, Kress W, Coucke P, Rifkin DB, De Paepe AM, Dietz HC: A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet. 2005, 37: 275-281. 10.1038/ng1511.CrossRefPubMed
41.
go back to reference Hoyles RK, Khan K, Shiwen X, Howat SL, Lindahl GE, Leoni P, du Bois RM, Wells AU, Black CM, Abraham DJ, Denton CP: Fibroblast-specific perturbation of transforming growth factor beta signaling provides insight into potential pathogenic mechanisms of scleroderma-associated lung fibrosis: exaggerated response to alveolar epithelial injury in a novel mouse model. Arthritis Rheum. 2008, 58: 1175-1188. 10.1002/art.23379.CrossRefPubMed Hoyles RK, Khan K, Shiwen X, Howat SL, Lindahl GE, Leoni P, du Bois RM, Wells AU, Black CM, Abraham DJ, Denton CP: Fibroblast-specific perturbation of transforming growth factor beta signaling provides insight into potential pathogenic mechanisms of scleroderma-associated lung fibrosis: exaggerated response to alveolar epithelial injury in a novel mouse model. Arthritis Rheum. 2008, 58: 1175-1188. 10.1002/art.23379.CrossRefPubMed
42.
go back to reference Denton CP, Zheng B, Evans LA, Shi-wen X, Ong VH, Fisher I, Lazaridis K, Abraham DJ, Black CM, de Crombrugghe B: Fibroblast-specific expression of a kinase-deficient type II transforming growth factor beta (TGFbeta) receptor leads to paradoxical activation of TGFbeta signaling pathways with fibrosis in transgenic mice. J Biol Chem. 2003, 278: 25109-25119. 10.1074/jbc.M300636200.CrossRefPubMed Denton CP, Zheng B, Evans LA, Shi-wen X, Ong VH, Fisher I, Lazaridis K, Abraham DJ, Black CM, de Crombrugghe B: Fibroblast-specific expression of a kinase-deficient type II transforming growth factor beta (TGFbeta) receptor leads to paradoxical activation of TGFbeta signaling pathways with fibrosis in transgenic mice. J Biol Chem. 2003, 278: 25109-25119. 10.1074/jbc.M300636200.CrossRefPubMed
43.
go back to reference Derrett-Smith EC, Dooley A, Khan K, Shi-wen X, Abraham D, Denton CP: Systemic vasculopathy with altered vasoreactivity in a transgenic mouse model of scleroderma. Arthritis Res Ther. 2010, 12: R69-10.1186/ar2986.PubMedCentralCrossRefPubMed Derrett-Smith EC, Dooley A, Khan K, Shi-wen X, Abraham D, Denton CP: Systemic vasculopathy with altered vasoreactivity in a transgenic mouse model of scleroderma. Arthritis Res Ther. 2010, 12: R69-10.1186/ar2986.PubMedCentralCrossRefPubMed
44.
go back to reference Wei J, Melichian D, Komura K, Hinchcliff M, Lam AP, Lafyatis R, Gottardi CJ, MacDougald OA, Varga J: Canonical Wnt signaling induces skin fibrosis and subcutaneous lipoatrophy: a novel mouse model for scleroderma?. Arthritis Rheum. 2011, 63: 1707-1717. 10.1002/art.30312.PubMedCentralCrossRefPubMed Wei J, Melichian D, Komura K, Hinchcliff M, Lam AP, Lafyatis R, Gottardi CJ, MacDougald OA, Varga J: Canonical Wnt signaling induces skin fibrosis and subcutaneous lipoatrophy: a novel mouse model for scleroderma?. Arthritis Rheum. 2011, 63: 1707-1717. 10.1002/art.30312.PubMedCentralCrossRefPubMed
45.
go back to reference Akhmetshina A, Palumbo K, Dees C, Bergmann C, Venalis P, Zerr P, Horn A, Kireva T, Beyer C, Zwerina J, Schneider H, Sadowski A, Riener MO, MacDougald OA, Distler O, Schett G, Distler JH: Activation of canonical Wnt signalling is required for TGF-beta-mediated fibrosis. Nat Commun. 2012, 3: 735-PubMedCentralCrossRefPubMed Akhmetshina A, Palumbo K, Dees C, Bergmann C, Venalis P, Zerr P, Horn A, Kireva T, Beyer C, Zwerina J, Schneider H, Sadowski A, Riener MO, MacDougald OA, Distler O, Schett G, Distler JH: Activation of canonical Wnt signalling is required for TGF-beta-mediated fibrosis. Nat Commun. 2012, 3: 735-PubMedCentralCrossRefPubMed
46.
go back to reference Avouac J, Palumbo K, Tomcik M, Zerr P, Dees C, Horn A, Maurer B, Akhmetshina A, Beyer C, Sadowski A, Schneider H, Shiozawa S, Distler O, Schett G, Allanore Y, Distler JH: Inhibition of activator protein 1 signaling abrogates transforming growth factor beta-mediated activation of fibroblasts and prevents experimental fibrosis. Arthritis Rheum. 2012, 64: 1642-1652. 10.1002/art.33501.CrossRefPubMed Avouac J, Palumbo K, Tomcik M, Zerr P, Dees C, Horn A, Maurer B, Akhmetshina A, Beyer C, Sadowski A, Schneider H, Shiozawa S, Distler O, Schett G, Allanore Y, Distler JH: Inhibition of activator protein 1 signaling abrogates transforming growth factor beta-mediated activation of fibroblasts and prevents experimental fibrosis. Arthritis Rheum. 2012, 64: 1642-1652. 10.1002/art.33501.CrossRefPubMed
47.
go back to reference Eferl R, Hasselblatt P, Rath M, Popper H, Zenz R, Komnenovic V, Idarraga MH, Kenner L, Wagner EF: Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1. Proc Natl Acad Sci USA. 2008, 105: 10525-10530. 10.1073/pnas.0801414105.PubMedCentralCrossRefPubMed Eferl R, Hasselblatt P, Rath M, Popper H, Zenz R, Komnenovic V, Idarraga MH, Kenner L, Wagner EF: Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1. Proc Natl Acad Sci USA. 2008, 105: 10525-10530. 10.1073/pnas.0801414105.PubMedCentralCrossRefPubMed
48.
go back to reference Nusslein-Volhard C, Wieschaus E: Mutations affecting segment number and polarity in Drosophila. Nature. 1980, 287: 795-801. 10.1038/287795a0.CrossRefPubMed Nusslein-Volhard C, Wieschaus E: Mutations affecting segment number and polarity in Drosophila. Nature. 1980, 287: 795-801. 10.1038/287795a0.CrossRefPubMed
49.
go back to reference Horn A, Palumbo K, Cordazzo C, Dees C, Akhmetshina A, Tomcik M, Zerr P, Avouac J, Gusinde J, Zwerina J, Roudaut H, Traiffort E, Ruat M, Distler O, Schett G, Distler JH: Hedgehog signaling controls fibroblast activation and tissue fibrosis in systemic sclerosis. Arthritis Rheum. 2012, 64: 2724-2733. 10.1002/art.34444.CrossRefPubMed Horn A, Palumbo K, Cordazzo C, Dees C, Akhmetshina A, Tomcik M, Zerr P, Avouac J, Gusinde J, Zwerina J, Roudaut H, Traiffort E, Ruat M, Distler O, Schett G, Distler JH: Hedgehog signaling controls fibroblast activation and tissue fibrosis in systemic sclerosis. Arthritis Rheum. 2012, 64: 2724-2733. 10.1002/art.34444.CrossRefPubMed
50.
go back to reference Horn A, Kireva T, Palumbo-Zerr K, Dees C, Tomcik M, Cordazzo C, Zerr P, Akhmetshina A, Ruat M, Distler O, Beyer C, Schett G, Distler JH: Inhibition of hedgehog signalling prevents experimental fibrosis and induces regression of established fibrosis. Ann Rheum Dis. 2012, 71: 785-789. 10.1136/annrheumdis-2011-200883.CrossRefPubMed Horn A, Kireva T, Palumbo-Zerr K, Dees C, Tomcik M, Cordazzo C, Zerr P, Akhmetshina A, Ruat M, Distler O, Beyer C, Schett G, Distler JH: Inhibition of hedgehog signalling prevents experimental fibrosis and induces regression of established fibrosis. Ann Rheum Dis. 2012, 71: 785-789. 10.1136/annrheumdis-2011-200883.CrossRefPubMed
51.
go back to reference Wei J, Fang F, Lam AP, Sargent JL, Hamburg E, Hinchcliff ME, Gottardi CJ, Atit R, Whitfield ML, Varga J: Wnt/beta-catenin signaling is hyperactivated in systemic sclerosis and induces Smad-dependent fibrotic responses in mesenchymal cells. Arthritis Rheum. 2012, 64: 2734-2745. 10.1002/art.34424.PubMedCentralCrossRefPubMed Wei J, Fang F, Lam AP, Sargent JL, Hamburg E, Hinchcliff ME, Gottardi CJ, Atit R, Whitfield ML, Varga J: Wnt/beta-catenin signaling is hyperactivated in systemic sclerosis and induces Smad-dependent fibrotic responses in mesenchymal cells. Arthritis Rheum. 2012, 64: 2734-2745. 10.1002/art.34424.PubMedCentralCrossRefPubMed
52.
go back to reference Thoua NM, Derrett-Smith EC, Khan K, Dooley A, Shi-Wen X, Denton CP: Gut fibrosis with altered colonic contractility in a mouse model of scleroderma. Rheumatology. 2012, 51: 1989-1998. 10.1093/rheumatology/kes191.CrossRefPubMed Thoua NM, Derrett-Smith EC, Khan K, Dooley A, Shi-Wen X, Denton CP: Gut fibrosis with altered colonic contractility in a mouse model of scleroderma. Rheumatology. 2012, 51: 1989-1998. 10.1093/rheumatology/kes191.CrossRefPubMed
53.
go back to reference Sonnylal S, Denton CP, Zheng B, Keene DR, He R, Adams HP, Vanpelt CS, Geng YJ, Deng JM, Behringer RR, de Crombrugghe B: Postnatal induction of transforming growth factor beta signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma. Arthritis Rheum. 2007, 56: 334-344. 10.1002/art.22328.CrossRefPubMed Sonnylal S, Denton CP, Zheng B, Keene DR, He R, Adams HP, Vanpelt CS, Geng YJ, Deng JM, Behringer RR, de Crombrugghe B: Postnatal induction of transforming growth factor beta signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma. Arthritis Rheum. 2007, 56: 334-344. 10.1002/art.22328.CrossRefPubMed
54.
go back to reference Sonnylal S, Shi-Wen X, Leoni P, Naff K, Van Pelt CS, Nakamura H, Leask A, Abraham D, Bou-Gharios G, de Crombrugghe B: Selective expression of connective tissue growth factor in fibroblasts in vivo promotes systemic tissue fibrosis. Arthritis Rheum. 2010, 62: 1523-1532. 10.1002/art.27382.CrossRefPubMed Sonnylal S, Shi-Wen X, Leoni P, Naff K, Van Pelt CS, Nakamura H, Leask A, Abraham D, Bou-Gharios G, de Crombrugghe B: Selective expression of connective tissue growth factor in fibroblasts in vivo promotes systemic tissue fibrosis. Arthritis Rheum. 2010, 62: 1523-1532. 10.1002/art.27382.CrossRefPubMed
55.
go back to reference Venalis P, Distler O, Lundberg IE, Schett G, Distler JH: Heart involvement in patients with systemic sclerosis is mimicked by Fra-2 transgenic mice. Ann Rheum Dis. 2012, 71 (Suppl 1): A46-CrossRef Venalis P, Distler O, Lundberg IE, Schett G, Distler JH: Heart involvement in patients with systemic sclerosis is mimicked by Fra-2 transgenic mice. Ann Rheum Dis. 2012, 71 (Suppl 1): A46-CrossRef
56.
go back to reference Drab M, Verkade P, Elger M, Kasper M, Lohn M, Lauterbach B, Menne J, Lindschau C, Mende F, Luft FC, Schedl A, Haller H, Kurzchalia TV: Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science. 2001, 293: 2449-2452. 10.1126/science.1062688.CrossRefPubMed Drab M, Verkade P, Elger M, Kasper M, Lohn M, Lauterbach B, Menne J, Lindschau C, Mende F, Luft FC, Schedl A, Haller H, Kurzchalia TV: Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science. 2001, 293: 2449-2452. 10.1126/science.1062688.CrossRefPubMed
57.
go back to reference Razani B, Engelman JA, Wang XB, Schubert W, Zhang XL, Marks CB, Macaluso F, Russell RG, Li M, Pestell RG, Di Vizio D, Hou H, Kneitz B, Lagaud G, Christ GJ, Edelmann W, Lisanti MP: Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem. 2001, 276: 38121-38138.CrossRefPubMed Razani B, Engelman JA, Wang XB, Schubert W, Zhang XL, Marks CB, Macaluso F, Russell RG, Li M, Pestell RG, Di Vizio D, Hou H, Kneitz B, Lagaud G, Christ GJ, Edelmann W, Lisanti MP: Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem. 2001, 276: 38121-38138.CrossRefPubMed
58.
go back to reference Samuel CS, Zhao C, Yang Q, Wang H, Tian H, Tregear GW, Amento EP: The relaxin gene knockout mouse: a model of progressive scleroderma. J Invest Dermatol. 2005, 125: 692-699. 10.1111/j.0022-202X.2005.23880.x.CrossRefPubMed Samuel CS, Zhao C, Yang Q, Wang H, Tian H, Tregear GW, Amento EP: The relaxin gene knockout mouse: a model of progressive scleroderma. J Invest Dermatol. 2005, 125: 692-699. 10.1111/j.0022-202X.2005.23880.x.CrossRefPubMed
59.
go back to reference Saito E, Fujimoto M, Hasegawa M, Komura K, Hamaguchi Y, Kaburagi Y, Nagaoka T, Takehara K, Tedder TF, Sato S: CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight skin mouse. J Clin Invest. 2002, 109: 1453-1462.PubMedCentralCrossRefPubMed Saito E, Fujimoto M, Hasegawa M, Komura K, Hamaguchi Y, Kaburagi Y, Nagaoka T, Takehara K, Tedder TF, Sato S: CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight skin mouse. J Clin Invest. 2002, 109: 1453-1462.PubMedCentralCrossRefPubMed
60.
go back to reference Gentiletti J, McCloskey LJ, Artlett CM, Peters J, Jimenez SA, Christner PJ: Demonstration of autoimmunity in the tight skin-2 mouse: a model for scleroderma. J Immunol. 2005, 175: 2418-2426.CrossRefPubMed Gentiletti J, McCloskey LJ, Artlett CM, Peters J, Jimenez SA, Christner PJ: Demonstration of autoimmunity in the tight skin-2 mouse: a model for scleroderma. J Immunol. 2005, 175: 2418-2426.CrossRefPubMed
61.
go back to reference Yamamoto T, Takagawa S, Katayama I, Yamazaki K, Hamazaki Y, Shinkai H, Nishioka K: Animal model of sclerotic skin. I: Local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol. 1999, 112: 456-462. 10.1046/j.1523-1747.1999.00528.x.CrossRefPubMed Yamamoto T, Takagawa S, Katayama I, Yamazaki K, Hamazaki Y, Shinkai H, Nishioka K: Animal model of sclerotic skin. I: Local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol. 1999, 112: 456-462. 10.1046/j.1523-1747.1999.00528.x.CrossRefPubMed
62.
go back to reference Kavian N, Servettaz A, Mongaret C, Wang A, Nicco C, Chéreau C, Grange P, Vuiblet V, Birembaut P, Diebold MD, Weill B, Dupin N, Batteux F: Targeting ADAM-17/notch signaling abrogates the development of systemic sclerosis in a murine model. Arthritis Rheum. 2010, 62: 3477-3487. 10.1002/art.27626.CrossRefPubMed Kavian N, Servettaz A, Mongaret C, Wang A, Nicco C, Chéreau C, Grange P, Vuiblet V, Birembaut P, Diebold MD, Weill B, Dupin N, Batteux F: Targeting ADAM-17/notch signaling abrogates the development of systemic sclerosis in a murine model. Arthritis Rheum. 2010, 62: 3477-3487. 10.1002/art.27626.CrossRefPubMed
Metadata
Title
Scleroderma pathogenesis: a pivotal role for fibroblasts as effector cells
Authors
Adrian J Gilbane
Christopher P Denton
Alan M Holmes
Publication date
01-06-2013
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 3/2013
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar4230

Other articles of this Issue 3/2013

Arthritis Research & Therapy 3/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.